4 results
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…
Approved WMORecruiting
To evaluate the long-term safety and performance of the HARPOON* MVRS for use in patients presenting with severe degenerative mitral regurgitation due to posterior leaflet prolapse in the post-market phase.
Approved WMORecruiting
To determine the dose-response relationship of VAY736 for key efficacy and safety parameters.
Approved WMORecruiting
Evaluation of the feasibility of intraoperative visualization of penile and tongue tumours using the fluorescent tracer EMI-137.